Latest news, reports, and more from the RedChip Nation.
Discovering Tomorrow's Blue Chips Today
May 5, 2020     Contact    
CytoDyn (OTCQB: CYDY) Targets Enrollment Completion for Phase 2 COVID-19 Trial by End of May


CytoDyn (OTCQB: CYDY), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced that the Company is expecting enrollment completion for its 75 patient, Phase 2 double blinded, placebo controlled, randomized study by the end of this month.


Why It Matters: CytoDyn has submitted a request to the FDA to grant expanded access, also known as “compassionate use,” to make leronlimab available for patients not eligible for participation in two ongoing clinical trials for coronavirus infections. Many severe and critically ill patients, who have received off-label immunomodulatory treatments for COVID-19, are excluded from participation in the Company’s Phase 2b/3 clinical trial and could potentially benefit from access to leronlimab under a compassionate use program. There are 49 COVID-19 patients who have enrolled for treatment with leronlimab through eIND. Four out of 11 critically ill patients with a multitude of pre-existing conditions survived after treatment, and of the next 38 patients, many were extubated, improved, or were discharged.


Key Quote: “We are very excited about the continuing positive responses from eIND patients following their treatment with leronlimab. We are equally excited about the prospects for patients should the FDA grant access to leronlimab under the compassionate use program.” – Nader Pourhassan, Ph.D., President & CEO


The Backstory: CytoDyn has successfully completed a Phase 3 pivotal trial with leronlimab in combination with standard antiretroviral therapies in HIV-infected treatment-experienced patients. CytoDyn completed the filing of its BLA in April 2020 to seek FDA approval for leronlimab as a combination therapy for highly treatment experienced HIV patients. CytoDyn is also conducting a Phase 3 investigative trial with leronlimab as a once-weekly monotherapy for HIV-infected patients. CytoDyn plans to initiate a registration-directed study of leronlimab monotherapy indication. If successful, it could support a label extension.



CytoDyn (CYDY) is a client of RedChip Companies, Inc. CYDY agreed to pay RedChip Companies, Inc., a $20,000 quarterly cash fee, beginning in February 2020, for RedChip investor awareness services.

Annovis Bio (NYSE American: ANVS) Announces Plans for New Phase II Clinical Trial to Treat 68 Parkinson’s and Alzheimer’s Patients


Annovis Bio (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease, Parkinson’s disease and other neurodegenerative diseases, announced that the protocol for its Phase 2 clinical study in PD and AD patients was submitted to the U.S. Food and Drug Administration (FDA). The Company has received no comments from the FDA and is therefore able to proceed with the launch of the clinical trial.


Why it Matters:The clinical trial is expected to take place at 10 sites across the US. The Company expects to begin recruitment and enrollment in May, with treatment starting in June. The Company believes the study will be completed before the end of 2020, but due to the COVID-19 pandemic, the study’s commencement may be delayed until later this summer and completion may be delayed until the first quarter of 2021.


Key Quote:“We decided to add an Alzheimer’s arm to our Parkinson’s study because we want to treat patients the exact same way, monitor them the exact same way, and measure the exact same biomarkers, transport proteins, inflammatory markers, synaptic and degenerative markers. Although this is a short study, for safety purposes we will also measure cognition and function.” - Maria Maccecchini, Ph.D., CEO


The Backstory:Headquartered in Berwyn, Pennsylvania, Annovis Bio is a clinical-stage, drug platform company addressing neurodegeneration, such as Alzheimer’s disease (AD), Parkinson’s disease (PD) and Alzheimer’s in Down Syndrome (AD-DS). We believe that we are the only company developing a drug for AD, PD and AD-DS that inhibits more than one neurotoxic protein and, thereby, improves the information highway of the nerve cell, known as axonal transport. When this information flow is impaired, the nerve cell gets sick and dies. We expect our treatment to improve memory loss and dementia associated with AD and AD-DS, as well as body and brain function in PD. We have an ongoing Phase 2a study in AD patients and plan to commence a second Phase 2a study in PD patients.



Annovis (ANVS) is a client of RedChip Companies, Inc. ANVS agreed to pay RedChip Companies, Inc. a $8,500 monthly cash fee, beginning in February 2020, for RedChip investor awareness services and consulting services.

Piedmont Lithium (NASDAQ: PLL) Files March 2020 Quarterly Report


Piedmont Lithium (NASDAQ: PLL) filed its March 2020 quarterly report highlighting recent accomplishments.


Key Highlights:

  • Chemical plant pre-feasibility study remains on track for delivery in Q2 2020
  • Plant permitting activities ongoing
  • Continued preliminary off-take, financing and strategic conversations, including companies from the lithium, mining, chemicals, battery, automotive and private equity sectors
  • Soil and rock chip sampling at the Project in North Carolina, United States, led to the discovery of five new spodumene-bearing pegmatites in areas that have not previously been explored

Upcoming Milestones:

  • Complete the chemical plant PFS and a fully integrated Scoping Study Update in Q2 2020
  • Finalize the bench scale lithium hydroxide testwork program and produce initial product samples in Q2 2020
  • Submit key chemical plant permit applications including a synthetic minor source air permit application
  • Build out project construction and sales & marketing teams
  • Continue offtake discussions for lithium hydroxide and by-product quartz, feldspar and mica
  • Continue to evaluate strategic partnering options

The Backstory: Piedmont Lithium holds a 100% interest in the Piedmont Lithium Project (“Project”) located within the world-class Carolina TinSpodumene Belt (“TSB”) and along trend to the Hallman Beam and Kings Mountain mines, historically providing most of the western world’s lithium between the 1950s and the 1980s. The TSB has been described as one of the largest lithium provinces in the world and is located approximately 25 miles west of Charlotte, North Carolina. It is a premier location for development of an integrated lithium business based on its favorable geology, proven metallurgy and easy access to infrastructure, power, R&D centers for lithium and battery storage, major high-tech population centers and downstream lithium processing facilities.



Piedmont Lithium (PLL) is a client of RedChip Companies, Inc. PLL agreed to pay RedChip Companies, Inc. a quarterly cash fee of $20,000, beginning in April 2019, for 12 months of RedChip investor awareness services.

SinglePoint (OTCQB: SING) Enters JV Agreement to Further Expand and Accelerate Opportunities in Response to Increased Demand in Hand Sanitizer Market


SinglePoint (OTCQB: SING) is ramping up efforts to meet inbound demand for hand sanitizer and other sanitizing products and recently entered a JV Agreement with Box-Bioscience as part of those efforts.


Why It Matters: The agreement will provide both parties with the capability to enhance supply and expand sales opportunities of hand sanitizer. The product is current sold in a variety of sizes ranging from 2oz to truckloads for bulk supply. With the successful rollout of Klen, SinglePoint has been approached by larger retailers to supply bulk products. This shift has set the stage for a Joint Venture between the two companies to supply hand sanitizer manufactured to the current FDA guidelines. Box has already completed orders with multiple accounts, including segments of Fortune 500 companies around the nation with new sales and inquiries happening daily.


Key Quote: “We are excited to work with SinglePoint to expand and grow our collective business. We have seen multiple Purchase Orders and we expect an increase over the coming months as many retailers and businesses change protocols around sanitizing. This is a true B2B play with nearly all businesses needing hand sanitizer for customers and employee's protection.” – Ryan Cowell, Founder Box Bioscience


The Backstory: The two companies, through the JV, will collaborate to manufacture and distribute sanitizing products. The initial priority has been focused on increasing production and sales of bulk hand sanitizer to meet the current demand. An increasing demand has come from non-traditional retail and well as manufacturing and other service businesses concerned with providing solutions to meet the new safety protocols, these businesses have been or are currently being undeserved to the increased demand. The JV has plans to quickly introduce additional products leveraging the Simplex + Virus Killer brand to potentially include wipes, spray, and nasal spray



SinglePoint, Inc. (SING) is a client of RedChip Companies, Inc. SING agreed to pay RedChip Companies, Inc. a $10,000 monthly cash fee, beginning in June 2019, for RedChip investor awareness services and consulting services.

Quote of the Week
"There is no passion to be found playing small - in settling for a life that is less than the one you are capable of living."
- Nelson Mandela
Latest Videos
This Week on RedChip TV: 3 Small-Cap Stocks that Could Win Big in 2020
Watch RedChip’s exclusive interviews with executives from three exciting small-cap companies: Annovis Bio (NYSE AMERICAN: ANVS), SPI Energy (NASDAQ: SPI), and BioVie (OTCQB: BIVI).
Watch Now
ANVS: Annovis Bio Webinar Replay (April 2020)
Annovis Bio (NYSE American: ANVS) is a clinical-stage, drug platform company addressing neurodegeneration, such as Alzheimer’s disease (AD), Parkinson’s disease (PD) and Alzheimer’s in Down Syndrome (AD-DS).
Watch Now
BioVie: Targeting Landmark Achievement in $500M Market
BioVie Inc. (OTCQB: BIVI) is a clinical-stage company developing innovative drug therapies for liver disease. The Company’s drug candidate, BIV201 (continuous infusion terlipressin), has an Orphan Drug designation for the treatment of refractory ascites, FDA Fast Track status, and US patent pending.
Watch Now
CytoDyn: Possible Treatment for COVID-19
CytoDyn (OTCQB: CYDY) received fast-track approval for two Phase 2 clinical trials of its leronlimab drug in COVID-19 patients. Results from initial patients treated under an Emergency IND from the FDA indicate leronlimab significantly reduces the cytokine storm caused by the coronavirus.
Watch Now
Esports Entertainment: First iGaming Company to List on NASDAQ
Esports Entertainment Group Inc. (NASDAQ: GMBL) is a licensed online gambling company with a specific focus on esports wagering and 18+ gaming. Esports Entertainment offers fantasy, pools, fixed odds and exchange style wagering on esports events in a licensed, regulated and secure platform to the global esports audience at In addition, Esports Entertainment intends to offer users from around the world the ability to participate in multi-player mobile and PC video game tournaments for cash prizes. Esports Entertainment is led by a team of industry professionals and technical experts from the online gambling and the video game industries, and esports.
Watch Now
EMRN: New Technology Leading Change in Global Seaborne Shipping
eMARINE Global (OTCQB: ERMN) is a provider of information and communications technology in the maritime industry. Specifically, eMARINE provides solutions for collection, integration and display of maritime information abroad and ashore by electronic means to enhance berth to berth navigation and related services.
Watch Now
SPI Energy: An Emerging Leader in the Global Solar Markets
Watch our exclusive interview with the COO of SPI Energy (NASDAQ: SPI). SPI is a global provider of photovoltaic (PV) solutions for business, residential, government, and utility customers and investors.
Watch Now
Annovis Bio: A Potential Game Changer in Alzheimer’s Treatment
Exclusive interview with Dr. Maria Maccecchini, Founder and CEO of Annovis Bio (NYSE American: ANVS), a clinical-stage, drug platform company addressing neurodegeneration, such as Alzheimer’s disease (AD), Parkinson’s disease (PD) and Alzheimer’s in Down Syndrome (AD-DS).
Watch Now
OLB Group: FinTech Stock with $10M+ Revenue Set for Big Growth
The OLB Group (OTC: OLBG) is led by a team of seasoned industry executives with extensive experience in payments, ecommerce, and mobile commerce. The Company has built and operates a suite of integrated fintech and payment facilitation products and services that is a blend of Shopify (NASDAQ: SHOP) and Square (NYSE: SQ) with added features and benefits.
Watch Now
Digital Ally CEO Interview: New Market Expansions Driving Revenue Growth
Digital Ally (NASDAQ: DGLY), headquartered in Lenexa, KS, specializes in the design and manufacturing of the highest quality video recording equipment and video analytic software. Digital Ally pushes the boundaries of technology in industries such as law enforcement, emergency management, fleet safety and security. Digital Ally’s complete product solutions include in-car and body cameras, cloud and local management software, and automatic recording technology. Digital Ally products are sold by domestic direct sales representatives and international distributors worldwide.
Watch Now
Order Small Stocks, Big Money Today!
Dave Gentry is the author of Small Stocks, Big Money: Interviews With Microcap Superstars. Published by Wiley, this first-hand perspective on the fast world of microcap investing is now available for purchase.
MidSouth Week in Review
Dividend suspensions hit record levels, including Royal Dutch Shell, who cut their dividend for the first time since the 1940’s.
Read More
Weekly Index Performance
Small-caps posted solid gains last week as larger cap indexes traded down modestly.
Read More
About RedChip
RedChip Companies, an Inc. 5000 company, is an international investor relations, media, and research firm focused on small-cap and mid-cap companies. Since 1992, RedChip has delivered concrete, measurable results for its clients through the most comprehensive service platform in the industry for small-cap and mid-cap companies. These services include a worldwide distribution network for its stock research written by analysts holding the CFA designation; retail and institutional roadshows in major U.S. cities; outbound marketing to stock brokers, RIAs, institutions, and family offices; a digital media investor relations platform that has generated over 2.3 million unique investor views; quarterly global online institutional and retail investor conferences that reach over 10,000 investors annually; "The RedChip Money Report" television show which airs in 100 million homes across the U.S. on The Family Channel; a weekly newsletter delivered to 60,000 investors; TV commercials in local and national markets; corporate and product videos; website design; and traditional investor relation services, which include press release writing, development of investor presentations, quarterly conference call script writing, strategic consulting, capital raising, and more.
RedChip Disclosure
RedChip Companies, Inc. research reports, company profiles and other investor relations materials, publications or presentations, including web content, are based on data obtained from sources we believe to be reliable but are not guaranteed as to accuracy and are not purported to be complete. As such, the information should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed in RedChip reports, company profiles, or other investor relations materials and presentations are subject to change. RedChip Companies and its affiliates may buy and sell shares of securities or options of the issuers mentioned on this website at any time.
RedChip Visibility is a division of RedChip Companies, Inc. and offers research services to paying clients. In the purview of Section 17(b) of the Securities Act of 1933 and in the interest of full disclosure, we call the reader's attention to the fact that the RedChip Companies Inc. is an investor relations firm hired by certain Companies to increase investor awareness to the small-cap equity community.
Stock market investing is inherently risky. RedChip Companies is not responsible for any gains or losses that result from the opinions expressed on this website, in its research reports, company profiles or in other investor relations materials or presentations that it publishes electronically or in print.
We strongly encourage all investors to conduct their own research before making any investment decision. For more information on stock market investing, visit the Securities and Exchange Commission ("SEC") at and view RedChip’s Disclosures.
Copyright © 2020 RedChip Companies, Inc. All Rights Reserved.
You are receiving this message because this email address has signed up to receive News Alerts.